Treats hormone receptor (HR)-positive, human epidermal growth factor receptor 2…. Sold as Verzenio. Every FDA application for this active ingredient: 2 branded and 1 generic.
As of Nov 13, 2026, FDA lists 3 applications for Abemaciclib (sold as Verzenio), first approved Sep 28, 2017, with 9 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2024 | Change | Beneficiaries |
|---|---|---|---|---|
| Verzenio | Part D | $1.06B | +40% | 11,239 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Sep 28, 2017 | VerzenioNDA 208716 · New molecular entity | Eli Lilly And Co | 12 | Marketed |
| Feb 26, 2018 | VerzenioNDA 208855 · New indication | Eli Lilly And Co | 0 | Marketed |
| — | AbemaciclibANDA 220238 | Qilu Pharmaceutical Co., Ltd. | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number. Drugs@FDA
